Latest News on IOVA

Financial News Based On Company


Advertisement
Advertisement

What Iovance Biotherapeutics Stock AMTAGVI Lung Cancer Push Means For Shareholders

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/what-iovance-biotherapeutics-stock-amtagvi-lung-cancer-push
Iovance Biotherapeutics reported Q3 2026 revenue of US$121.47 million and reaffirmed full-year guidance of US$410-420 million, signaling confidence in its TIL platform. The company's strategy to seek a broad second-line lung cancer indication for Amtagvi in 2027 and expand to 110 treatment centers suggests a shift from a niche melanoma product to a wider solid tumor franchise. This expansion, along with planned 2027 price increases for Amtagvi and Proleukin, indicates a focus on real-world adoption and commercial traction, which is crucial for reducing cash burn and increasing long-term equity value.

Key facts: Iovance Reports $122M Q3 Revenue; 2027 AMTAGVI Lung Trial

https://www.tradingview.com/news/tradingview:4e88c530f8c6f:0-key-facts-iovance-reports-122m-q3-revenue-2027-amtagvi-lung-trial/
Iovance Biotherapeutics Inc. (IOVA) reported third-quarter 2026 revenue of $122 million from AMTAGVI and PROLEUKIN, setting full-year 2026 revenue guidance at $410 million to $420 million. The company plans to seek expanded AMTAGVI approval for second-line lung cancer in 2027 and will also initiate a first-line study that year.

Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb

https://www.tradingview.com/news/marketbeat:e43814cc9094b:0-iovance-biotherapeutics-targets-2027-lung-cancer-filing-as-amtagvi-sales-climb/
Iovance Biotherapeutics is planning to seek a lung cancer indication for its AMTAGVI cell therapy in 2027, while also expanding its melanoma treatment network and advancing other studies. The company reported strong third-quarter sales of AMTAGVI and PROLEUKIN, raising its 2026 revenue guidance. Iovance also announced price increases for both therapies effective January 1, 2027, and is progressing with international approvals and production capabilities.

A London conference presentation by Iovance leaders is planned, with a webcast available.

https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-zubvm605faku.html
Iovance Biotherapeutics (NASDAQ: IOVA) announced that its senior leadership will present at the 2026 Jefferies Global Healthcare Conference in London on November 16, 2026, at 11:00 a.m. GMT / 6:00 a.m. EST. A live and archived webcast of the fireside chat will be accessible via the company's investor relations website. The company specializes in tumor infiltrating lymphocyte (TIL) therapies for cancer patients.

Iovance Biotherapeutics (IOVA) Reaffirmed Guidance And Shared Lifileucel Data, Is It 55% Undervalued?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovance-biotherapeutics-iova-reaffirmed-guidance-and-shared
Iovance Biotherapeutics (IOVA) has reaffirmed its 2026 revenue outlook of US$410 million to US$420 million and reported improved Q3 results. Despite a recent 44% share price slide, a Simply Wall St narrative suggests the company is 55% undervalued at $8.09 compared to a fair value of $18, attributing the discount to past market worries. However, market ratios, like a P/S of 9.9x, present a tougher view compared to its fair ratio of 8.5x and a peer average of 5x.
Advertisement

Iovance Biotherapeutics to Present at Upcoming Conference

https://www.globenewswire.com/news-release/2026/11/12/3402218/0/en/iovance-biotherapeutics-to-present-at-upcoming-conference.html
Iovance Biotherapeutics announced its senior leadership will present at the 2026 Jefferies Global Healthcare Conference in London on November 16, 2026. The company, a leader in TIL cell therapies for solid tumors, will host a fireside chat to discuss its advancements, including the FDA-approved Amtagvi®. A live and archived webcast of the presentation will be available on the company's investor relations website.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-iovance-biotherapeutics-inc---iova-302937404.html
Pomerantz LLP is investigating potential securities fraud claims against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) on behalf of its investors. The investigation follows a significant drop in Iovance's stock price after the company reported "consistent with previously reported results" data from its Phase 2 IOV-LUN-202 clinical trial, which showed a lower response rate in a subgroup compared to standard treatment. Investors are encouraged to contact Pomerantz LLP for more information.

Will Earnings And Lung Cancer Data Change Iovance Stock Narrative

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/will-earnings-and-lung-cancer-data-change-iovance-stock-narr
Iovance Biotherapeutics reported Q3 2026 revenue of US$121.47 million, a reduced net loss of US$22.27 million, and reaffirmed its full-year revenue guidance of US$410 million to US$420 million. The company also presented updated lifileucel data in non-squamous metastatic non-small-cell lung cancer, showing a 59.1% objective response rate in a biomarker-enriched subgroup. These developments support Iovance's precision TIL approach and provide a clearer path for its clinical development, while the investment narrative focuses on execution against revenue targets and managing dilution risk.

Form SCHEDULE 13G IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13G+IOVANCE+BIOTHERAPEUTICS%2C+Filed+by%3A+STATE+STREET+CORP/27319381.html
STATE STREET CORPORATION has filed a Schedule 13G form regarding its ownership in IOVANCE BIOTHERAPEUTICS INC, showing an aggregate beneficial ownership of 21,695,003 shares, representing 4.8% of the common stock. The filing indicates that State Street Corporation holds shared voting power over 20,523,410 shares and shared dispositive power over 21,695,003 shares. This filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

State Street shares voting power over 20.5M Iovance (IOVA) shares. Its ownership stake is larger.

https://www.stocktitan.net/sec-filings/IOVA/schedule-13g-iovance-biotherapeutics-inc-passive-investment-disclosur-40a1161dd666.html
State Street Corporation has reported a 4.8% beneficial ownership stake in Iovance Biotherapeutics, Inc. (IOVA) as of September 30, 2026, holding 21,695,003 shares. The firm also disclosed shared voting power over 20,523,410 shares and shared dispositive power over the full 21,695,003 shares. This information was filed via a Schedule 13G form with the SEC.
Advertisement

Weekly Recap: Q3 revenue up 80% and lifileucel response rates

https://www.tradingview.com/news/tradingview:729212f4052e4:0-weekly-recap-q3-revenue-up-80-and-lifileucel-response-rates/
Iovance Biotherapeutics Inc (NASDAQ:IOVA) reported an 80% increase in Q3 2026 revenue, reaching $121.5 million, and reaffirmed its 2026 revenue guidance. The company also shared positive response rates for its lifileucel cancer treatment and announced conditional Australian authorization for Amtagvi. Several firms raised Iovance's price targets, and institutional investors adjusted their holdings in the company.

Citizens maintains Iovance Biotherapeutics at Market Outperform, raises price target to $12 from $8

https://www.tradingview.com/news/tradingview:0ab2dd9d1f1a4:0-citizens-maintains-iovance-biotherapeutics-at-market-outperform-raises-price-target-to-12-from-8/
Citizens maintained an "Market Outperform" rating for Iovance Biotherapeutics and increased its price target to $12 from $8, representing a 50% hike. This new target implies a 55% upside from the stock's closing price of $7.74 on November 5. Other recent analyst actions on Iovance Biotherapeutics include UBS maintaining a Neutral rating with an $8 target, Barclays an Overweight with an $18 target, and Baird a Neutral with an $11 target.

Iovance Biotherapeutics Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:c117f3197094b:0-iovance-biotherapeutics-q3-earnings-call-highlights/
Iovance Biotherapeutics reported record third-quarter revenue of $122 million, an 80% increase year-over-year, driven by AMTAGVI sales exceeding $100 million. The company reaffirmed its 2026 revenue guidance of $410 million to $420 million and expects cash resources to last into 2029. Iovance also outlined plans for future approvals in non-small cell lung cancer and other cancers, expanding its treatment network and pipeline programs.

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

https://www.tradingview.com/news/zacks:259429e13094b:0-iova-q3-earnings-beat-on-amtagvi-sales-and-lower-r-d-costs/
Iovance Biotherapeutics (IOVA) reported a narrower-than-expected loss and an 80.1% increase in Q3 2026 revenues, driven by robust sales of its melanoma cell therapy, Amtagvi, which surpassed $100 million in quarterly U.S. sales for the first time. Despite the positive results, the stock fell 11%, possibly due to broader market weakness. The company also raised its gross margin guidance and reaffirmed its full-year 2026 revenue outlook, while advancing Amtagvi's reach and pipeline into lung and other cancers.

Iovance Biotherapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62920328/iovance-biotherapeutics-q3-2026-earnings-call-transcript
Iovance Biotherapeutics reported record-breaking Q3 2026 results with $122 million in revenue, an 80% year-over-year increase, driven by strong AMTAGVI sales exceeding $100 million. The company expanded its authorized treatment center network and is progressing its TIL platform for metastatic non-small cell lung cancer, with an sBLA planned for 2027. Iovance maintains a robust cash position, expected to fund operations into 2029, and reaffirmed its full-year revenue guidance of $410 to $420 million.
Advertisement

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

https://finance.yahoo.com/healthcare/articles/iovance-biotherapeutics-reports-record-third-120000183.html
Iovance Biotherapeutics announced record third-quarter 2026 revenue of approximately $122 million, an 80% increase year-over-year, driven by strong U.S. Amtagvi demand. The company is on track to meet its full-year revenue guidance of $410-$420 million and reported positive clinical trial results across its pipeline, including a 24.6% objective response rate in metastatic non-small-cell lung cancer and a 55.6% confirmed ORR in sarcomas, with several registrational trials underway. Iovance also highlighted its expanding authorized treatment center network and strong financial position, expecting current cash to fund operations into 2029.

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/iovance-biotherapeutics-reports-record-third-quarter-2026-revenue-of-122m-business-achievements-and-corporate-updates/2462817
Iovance Biotherapeutics announced record third-quarter 2026 revenue of approximately $122 million, driven by strong U.S. Amtagvi demand and improved gross margins. The company achieved key milestones, including treating over 1,000 commercial Amtagvi patients and reporting positive results from its IOV-LUN-202 trial for metastatic non-small-cell lung cancer. Iovance reaffirmed its full-year 2026 revenue guidance of $410 to $420 million and outlined progress in its global expansion and clinical pipeline, including registrational trials for various cancer indications.

A cancer treatment trial found a 59.1% response rate in selected lung cancer patients

https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-reports-record-third-quarter-2026-revenue-of-jbnkoph7isi0.html
Iovance Biotherapeutics reported record third-quarter 2026 revenue of approximately $122 million, an increase of 80% year-over-year, and maintained its full-year guidance. The company highlighted positive clinical trial results, including a 24.6% objective response rate in non-squamous metastatic non-small-cell lung cancer patients, which rose to 59.1% in a biomarker-selected subgroup, leading to a new registrational trial. Iovance also reported a 55.6% confirmed response rate in sarcoma patients and is advancing multiple other pipeline programs and global commercial expansion for Amtagvi.

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

https://www.globenewswire.com/news-release/2026/11/05/3396260/0/en/iovance-biotherapeutics-reports-record-third-quarter-2026-revenue-of-122m-business-achievements-and-corporate-updates.html
Iovance Biotherapeutics announced record third-quarter 2026 revenue of approximately $122 million, marking an 80% increase year-over-year, driven by strong U.S. Amtagvi demand and an improved gross margin of 60%. The company reported positive clinical trial results for its IOV-LUN-202 trial in mNSCLC and SARATOGA trial in soft tissue sarcomas, with several registrational trials underway and plans for global expansion for Amtagvi. Iovance also highlighted a strong financial position with $382 million in cash, expected to fund operations into 2029.

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

https://biobuzz.io/news/iovance-reports-updated-iov-lun-202-results-and-adds-precision-til-strategy/
Iovance Biotherapeutics announced updated results from its Phase 2 IOV-LUN-202 trial, showing a 24.6% objective response rate (ORR) in 69 previously treated non-squamous metastatic Non-Small Cell Lung Cancer (mNSCLC) patients. A new biomarker-enriched subgroup, defined by KRAS wild-type, HER2 wild-type, and smoking status, demonstrated a 59.1% ORR. This precision TIL strategy will be further evaluated in the POSI TIL ITY cohort within the IOV-LUN-202 trial, with registrational intent.
Advertisement

Iovance Biotherapeutics, Inc. (IOVA) Seasonal returns chart

https://au.finance.yahoo.com/quote/IOVA/seasonality/
The article provides a seasonal returns chart for Iovance Biotherapeutics, Inc. (IOVA), showing the average monthly price return from 2016 to 2026. It also includes real-time stock data, historical seasonality options for 3, 5, 10, and 20 years, and information about the upcoming Q3 2026 earnings call.

UBS maintains Iovance Biotherapeutics at Neutral, raises price target to $8 from $7

https://www.tradingview.com/news/tradingview:0c77d952c0cf1:0-ubs-maintains-iovance-biotherapeutics-at-neutral-raises-price-target-to-8-from-7/
UBS has reiterated its "Neutral" rating for Iovance Biotherapeutics and increased its price target for the company's stock from $7 to $8, representing a 14.3% rise. This new price target is consistent with the stock's closing price of $8.02 on November 2. Investors can find more detailed analyst data and ratings for Iovance Biotherapeutics on the Forecasts tab and track all past and future recommendations in the News Flow section.

Iovance Gears Up to Report Q3 Earnings: Here's What to Expect

https://www.tradingview.com/news/zacks:790eb178c094b:0-iovance-gears-up-to-report-q3-earnings-here-s-what-to-expect/
Iovance Biotherapeutics (IOVA) is expected to surpass earnings expectations for its third-quarter 2026 results, reporting on November 5. The company's sales are estimated at $117.7 million, with a projected loss of 9 cents per share, driven primarily by its newly marketed TIL therapy, Amtagvi, and the IL-2 product, Proleukin. The article also highlights positive predictions based on Iovance's Earnings ESP of +44.44% and a Zacks Rank #2, suggesting a strong likelihood of an earnings beat.

Iovance Adds Biomarker Selection to Lifileucel Lung Cancer Trial

https://www.clinicaltrialvanguard.com/news/iovance-adds-biomarker-selection-to-lifileucel-lung-cancer-trial/
Iovance Biotherapeutics is introducing a biomarker-enriched patient selection strategy for its lifileucel TIL therapy program in non-small cell lung cancer, as revealed in an October 29 filing. This "precision TIL strategy" comes after unselected patients in Cohorts 1 and 2 of the Phase 2 IOV-LUN-202 trial did not show sufficient response, signaling a pivot to improve outcomes and define a clearer registration path. The company will need to demonstrate the biomarker's validity and predictive power to support future FDA discussions.

Is 50% Crash Risk For Iovance Stock Real?

https://www.trefis.com/stock/iova/articles/621497/is-50-crash-risk-for-iovance-stock-real/2026-10-30
Iovance Biotherapeutics (IOVA) has a history of significant stock drops during market shocks, averaging a 40.0% decline, with some recoveries taking nearly two years. Despite recent revenue growth and reduced operating losses, the company remains unprofitable and heavily reliant on a single product, Amtagvi. Its cash reserves are projected to last only into the second half of 2028, making free cash flow a critical metric to watch for investors.
Advertisement

IOVA Stock Collapses As Traders Flee Biotech High‑Flier

https://stockstotrade.com/news/iovance-biotherapeutics-inc-iova-news-2026_10_30/
Iovance Biotherapeutics Inc. (IOVA) stock experienced a significant collapse, trading down by over 10% and plunging 35.4% intraday due to concerns over clinical trial developments. This rapid decline indicates a violent repricing as traders reassess risk and exit positions. Despite a solid balance sheet with ample cash and low debt, the market is signaling that previous high valuations were unsustainable given deep earnings losses and heavy R&D spend.

Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Cut to $14.2, Implies 4% Downside

https://www.tradingview.com/news/tradingview:9bf362daafb0e:0-iovance-biotherapeutics-inc-stock-12-month-price-target-cut-to-14-2-implies-4-downside/
The average 12-month price target for Iovance Biotherapeutics, Inc. stock has been reduced from $14.4 to $14.2 by 10 analysts, suggesting a potential 4% downside from the Oct. 28 closing price. Despite this reduction, the consensus rating for the stock remains "Buy," with 8 Buy recommendations and 2 Holds.

IOVA: IOV-LUN-202 showed ~25% ORR, with biomarker-enriched response reaching 59.1%

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4383299:0-iova-iov-lun-202-showed-25-orr-with-biomarker-enriched-response-reaching-59-1/
Iovance Biotherapeutics (IOVA) announced that its Lifileucel treatment achieved a ~25% Overall Response Rate (ORR) in 69 previously treated Non-Small Cell Lung Cancer (NSCLC) patients. A biomarker-enriched subgroup showed a significantly higher ORR of 59.1%. Enrollment for the POSITILITY study is slated for November 2026, with the OPTILISM study planned for 2027.

A lung cancer trial found responses in nearly 6 in 10 selected patients, versus about 1 in 4 overall.

https://www.stocktitan.net/news/IOVA/iovance-reports-updated-iov-lun-202-results-and-adds-precision-til-urj0ii61jdmu.html
Iovance Biotherapeutics announced updated Phase 2 trial results for its TIL therapy, lifileucel, in metastatic non-small-cell lung cancer (mNSCLC). While the overall objective response rate was 24.6%, a biomarker-enriched subgroup (KRAS wild-type, HER2 wild-type, and current/former smoking) showed a significantly higher response rate of 59.1%. These findings support a precision TIL strategy, with plans for a registrational study (POSITILITY) to begin enrollment in November 2026 and a supplemental approval application in 2027.

Can Iovance Stock Fall 50%?

https://www.trefis.com/stock/iova/articles/621236/can-iovance-stock-fall-50/2026-10-29
Iovance Biotherapeutics (IOVA) stock has historically experienced significant declines, but its future depends heavily on the success of its Amtagvi therapy, which currently drives most of its revenue. Amtagvi's sales are rapidly increasing due to strong patient demand and expanding treatment locations, contributing to a substantial rise in Iovance's stock price over the past year. While the company still operates at a loss, its financial performance is improving, with management focused on revenue growth, margin expansion, and cost management to achieve profitability.
Advertisement

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

https://www.globenewswire.com/news-release/2026/10/29/3391108/0/en/iovance-reports-updated-iov-lun-202-results-and-adds-precision-til-strategy-for-second-line-metastatic-non-small-cell-lung-cancer-mnsclc.html
Iovance Biotherapeutics announced updated results from its Phase 2 IOV-LUN-202 trial, showing a 24.6% objective response rate in non-squamous mNSCLC patients. A new biomarker-enriched precision TIL strategy achieved a 59.1% ORR in a KRAS wild-type, HER2 wild-type, and current/former smoker subgroup. The company plans to initiate the POSITILITY trial in November 2026 to prospectively evaluate this strategy and intends to pursue a supplemental Biologics License Application (sBLA) in 2027.

Iovance Biotherapeutics to Host Webcast on Positive Data

https://www.globenewswire.com/news-release/2026/10/28/3390870/0/en/iovance-biotherapeutics-to-host-webcast-on-positive-data-for-til-therapy-in-metastatic-non-small-cell-lung-cancer-mnsclc-and-broader-precision-medicine-strategy.html
Iovance Biotherapeutics will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. ET to discuss positive results from its IOV-LUN-202 Phase 2 registrational cohorts for lifileucel TIL therapy in metastatic non-small cell lung cancer (mNSCLC). The webcast will also provide an update on the company's broader precision medicine strategy for its TIL platform in mNSCLC. Iovance is a commercial biotechnology company specializing in tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors, with its first FDA-approved treatment, Amtagvi®, for advanced melanoma.

Iovance Biotherapeutics, Inc. (1IOVA.MI) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/1IOVA.MI/
Iovance Biotherapeutics, Inc. (1IOVA.MI) provides its stock price, news, quotes, and historical data, showing a recent dip of 3.40% as of October 2. The company, a commercial-stage biopharmaceutical firm, focuses on developing and commercializing cell therapies for various cancers, including metastatic melanoma, cervical cancer, and non-small cell lung cancer. Key financial highlights and performance metrics are detailed, including a 438.10% year-to-date return, significantly outperforming the S&P 500.

Iovance Biotherapeutics to Report Third Quarter 2026

https://www.globenewswire.com/news-release/2026/10/27/3388814/0/en/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026.html
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) will host a conference call and live audio webcast on Thursday, November 5, 2026, at 8:30 a.m. ET to announce its third-quarter 2026 financial results and provide corporate updates. The company is a commercial biotechnology firm specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer patients, with its FDA-approved Amtagvi® (lifileucel) already available in three global markets. Interested parties can register for the webcast on the company's investor relations website.

Iovance reports 50% response rate in sarcoma therapy trial

https://www.investing.com/news/company-news/iovance-reports-50-response-rate-in-sarcoma-therapy-trial-93CH-4972165
Iovance Biotherapeutics Inc. announced promising results from a pilot trial of its lifileucel therapy for metastatic undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, showing a 50% confirmed objective response rate among evaluable patients. The therapy's safety profile was consistent with previous findings, and the company is now enrolling patients for a registrational Phase 2 trial (SARATOGA) after receiving fast track designation from the FDA.
Advertisement

A one-time cancer treatment shrank tumors in 4 of 8 patients with rare sarcomas.

https://www.stocktitan.net/news/IOVA/iovance-announces-data-showing-durable-responses-with-lifileucel-til-k53e588t501d.html
Iovance Biotherapeutics announced promising results from a pilot trial of its one-time lifileucel monotherapy in advanced soft tissue sarcomas, specifically undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). The study showed a 50% confirmed objective response rate among eight evaluable patients, with all four partial responses ongoing at the data cutoff. This efficacy is considered unprecedented for these difficult-to-treat cancers, and the company is rapidly enrolling patients for its Phase 2 SARATOGA registrational trial.

Weekly Recap: Iovance Phase 2 melanoma ORR 62.5% and $304M cash runway

https://www.tradingview.com/news/tradingview:10e1863ef0418:0-weekly-recap-iovance-phase-2-melanoma-orr-62-5-and-304m-cash-runway/
Iovance Biotherapeutics (NASDAQ:IOVA) reported positive Phase 2 data for its frontline melanoma treatment, showing a 62.5% overall response rate (ORR) and 19.8 months of progression-free survival (PFS) with lifileucel plus pembrolizumab. The company also confirmed a cash runway into the second half of 2028 with approximately $304 million in cash and investments. Additionally, Iovance received FDA Fast Track designation for UPS/DDLPS indications.

Jefferies Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $20

https://www.moomoo.com/news/post/1002220853/jefferies-maintains-iovance-biotherapeutics-iovaus-with-buy-rating-maintains-target
Jefferies has reiterated its "Buy" rating on Iovance Biotherapeutics (IOVA.US), maintaining a target price of $20. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Iovance sees long-term response for Amtagvi in first-line melanoma (IOVA:NASDAQ)

https://seekingalpha.com/news/4656709-iovance-sees-long-term-response-amtagvi-first-line-melanoma
Iovance Biotherapeutics' Amtagvi, when combined with Merck's Keytruda, demonstrated a 62.5% objective response rate and a 29.2% complete response rate in first-line melanoma patients. This long-term response was observed after a median follow-up in an analysis of phase 2 data.

Iovance Biotherapeutics, Inc. (IOVA) stock price, news, quote and history

https://au.finance.yahoo.com/quote/IOVA/
This article provides detailed stock information for Iovance Biotherapeutics, Inc. (IOVA), including its current price, after-hours trading, historical data, and key financial metrics. It also shows a summary of valuation measures, profitability, and balance sheet highlights. The content is presented as a snapshot of the company's financial performance and market activity.
Advertisement

Iovance Biotherapeutics Reports 62.5% ORR and No-Reached Median OS in Final Phase 2 Analysis of Lifileucel Plus Pembrolizumab for Frontline Advanced Melanoma

https://www.quiverquant.com/news/Iovance+Biotherapeutics+Reports+62.5%25+ORR+and+No-Reached+Median+OS+in+Final+Phase+2+Analysis+of+Lifileucel+Plus+Pembrolizumab+for+Frontline+Advanced+Melanoma
Iovance Biotherapeutics announced compelling final Phase 2 results for its lifileucel combined with pembrolizumab therapy for frontline advanced melanoma, showing a 62.5% objective response rate and a median overall survival not yet reached after more than four years. These findings, presented at the ESMO Congress 2026, highlight the treatment's potential to address a significant unmet need for patients who do not respond to existing immunotherapies. The positive data supports the ongoing Phase 3 TILVANCE-301 trial, aiming for regulatory approval and broader application of this combination therapy.

Iovance Biotherapeutics, Inc. Estimates – NASDAQ:IOVA

https://www.tradingview.com/symbols/NASDAQ-IOVA/financials-estimates/?category=cash_flow
This article provides an overview of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform allows for comparing actual results with average, high, and low estimates, and visualizing trends over time.

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

https://www.globenewswire.com/news-release/2026/10/23/3387397/0/en/iovance-presents-new-data-at-esmo-2026-demonstrating-deep-durable-responses-with-lifileucel-til-cell-therapy-plus-pembrolizumab-in-frontline-advanced-melanoma.html
Iovance Biotherapeutics presented final Phase 2 data at ESMO 2026 for lifileucel combined with pembrolizumab in frontline advanced melanoma, showing a 62.5% objective response rate and a 29.2% complete response rate. The median overall survival was not reached at over four years of follow-up, indicating deep and durable responses. These results support the ongoing TILVANCE-301 Phase 3 trial, aiming for earlier use and potential approval of this combination therapy.

Iovance Biotherapeutics stock hits 52-week high at 15.32 USD By Investing.com

https://au.investing.com/news/stock-market-news/iovance-biotherapeutics-stock-hits-52week-high-at-1532-usd-93CH-4705016
Iovance Biotherapeutics (IOVA) stock reached a new 52-week high of $15.32, marking a 555% increase over the past year. This milestone follows strong second-quarter results with Amtagvi revenue exceeding expectations and several analysts raising their price targets and maintaining positive ratings due to confidence in the company's growth trajectory. The biotech firm, which commands a market capitalization of $6.89 billion, continues to advance its clinical pipeline of innovative cancer therapies.

Philadelphia’s Iovance to Present TIL Cell Therapy Data in Melanoma and Soft Tissue Sarcomas at ESMO 2026

https://biobuzz.io/news/philadelphias-iovance-to-present-til-cell-therapy-data-in-melanoma-and-soft-tissue-sarcomas-at-esmo-2026/
Iovance Biotherapeutics will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2026, including new clinical data for advanced melanoma and initial data for two soft tissue sarcomas. The presentations will cover findings from a pilot clinical trial on undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), as well as final Phase 2 results for lifileucel combined with pembrolizumab in frontline advanced melanoma. Additionally, the company will share translational and real-world evidence for lifileucel in non-small cell lung cancer (NSCLC) and advanced melanoma.
Advertisement

Iovance Biotherapeutics stock hits 52-week high at 15.32 USD

https://www.investing.com/news/company-news/iovance-biotherapeutics-stock-hits-52week-high-at-1532-usd-93CH-4963276
Iovance Biotherapeutics (IOVA) stock reached a new 52-week high of $15.32, with a staggering 555% increase over the past year. Despite an InvestingPro analysis suggesting the stock is overvalued, growing investor confidence in its cancer therapies is evident. Analysts from UBS, Goldman Sachs, Wells Fargo, and TD Cowen have all raised their price targets following strong Q2 results and increased revenue guidance for 2026.

Iovance Biotherapeutics stock hits 52-week high at 15.32 USD By Investing.com

https://in.investing.com/news/stock-market-news/iovance-biotherapeutics-stock-hits-52week-high-at-1532-usd-93CH-5645712
Iovance Biotherapeutics (IOVA) stock recently reached a new 52-week high of $15.32, with a year-over-year increase of 555%. Despite its current valuation appearing overvalued by InvestingPro analysis, the company reported strong Q2 results, with Amtagvi and Proleukin revenues surpassing estimates. This performance has led several analysts, including UBS, Goldman Sachs, Wells Fargo, and TD Cowen, to raise their price targets and maintain positive ratings, reflecting growing investor confidence in its innovative cancer therapies.

Las ETF que invierten en acciones de Iovance Biotherapeutics Inc

https://es.tradingview.com/symbols/XETR-2LB/etfs/
This article lists various Exchange Traded Funds (ETFs) that hold shares of Iovance Biotherapeutics Inc, providing detailed financial information for each fund. The list is organized by market value and includes data on weight, issuer, management style, expense ratio, assets under management (AUM), price, and total return. It serves as a resource for investors interested in Iovance Biotherapeutics shares through diversified ETF investments.

Iovance Biotherapeutics stock hits 52-week high at 15.32 USD By Investing.com

https://ca.investing.com/news/stock-market-news/iovance-biotherapeutics-stock-hits-52week-high-at-1532-usd-93CH-4893847
Iovance Biotherapeutics (IOVA) stock reached a new 52-week high of $15.32, reflecting a 555% increase over the past year. Despite concerns about overvaluation, the company reported strong Q2 results, with Amtagvi and Proleukin exceeding revenue estimates. Several analysts, including UBS, Goldman Sachs, Wells Fargo, and TD Cowen, raised their price targets and maintained positive ratings, citing confidence in the company's growth and innovative therapies.

Jefferies keeps USD 20 target for Iovance Biotherapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/jefferies-keeps-usd-20-target-for-iovance-biotherapeutics-stock/70377913
Jefferies has reiterated its USD 20 price target and Buy rating for Iovance Biotherapeutics (IOVA). The company reported Q2 2026 revenue of USD 99.31 million, a 65.70% year-over-year increase, while its stock was trading at USD 14.82 on Nasdaq and EUR 13.21 at Lang & Schwarz on October 20, 2026. This target suggests a potential upside of 34.95% from the Nasdaq price, reflecting both growth and the inherent uncertainties of a commercial-stage biotech company with a negative trailing valuation.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement